CD33 and acute myeloid leukemia: For example, using a 4-1BB-based CAR to engineer dendritic cells, researchers have shown that these CAR-DCs can produce IL-12, enhancing the effectiveness of anti-CD33 CAR-T-cell therapy for acute myeloid leukemia (AML).